---
title: "Victall: Wulanchabu Taizheng plans to reduce its holdings by no more than 0.36% of its shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225046641.md"
description: "According to the Zhitong Finance APP, Victall announced that Ulanqab Taizheng Shenghong Equity Investment Fund (Limited Partnership) (referred to as \"Ulanqab Taizheng\") plans to reduce its holdings in the company through centralized bidding or block trading within three months after the announcement date (from January 21, 2025, to April 20, 2025), totaling no more than 1.4311 million shares, accounting for no more than 0.36% of the company's total share capital"
datetime: "2025-01-15T12:03:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225046641.md)
  - [en](https://longbridge.com/en/news/225046641.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225046641.md)
---

# Victall: Wulanchabu Taizheng plans to reduce its holdings by no more than 0.36% of its shares

According to the announcement from Victall (605001.SH), the Ulanqab Taizheng Shenghong Equity Investment Fund (Limited Partnership) (referred to as "Ulanqab Taizheng") plans to reduce its holdings in the company through centralized bidding or block trading within three months from the date of the announcement (from January 21, 2025, to April 20, 2025), totaling no more than 1.4311 million shares, which does not exceed 0.36% of the company's total share capital

### Related Stocks

- [605001.CN](https://longbridge.com/en/quote/605001.CN.md)

## Related News & Research

- [Orkla (OB:ORK) Margin Improvement Challenges Cautious Earnings Narratives Heading Into Q1 2026](https://longbridge.com/en/news/287134604.md)
- [Aperture AC Announces the Pricing of $90,000,000 Initial Public Offering | APUR Stock News](https://longbridge.com/en/news/287124227.md)
- [Obamacare Meltdown? Sharp ACA Enrollment Drop Expected As Pandemic-Era Subsidies End](https://longbridge.com/en/news/287067300.md)
- [BYD is struggling to meet demand for new fast-charging EVs as orders reach 100K, 60K](https://longbridge.com/en/news/287109883.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)